| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | Kinase inhibitors | US14198964 | 2014-03-06 | US09321721B2 | 2016-04-26 | Thomas C. Malone; C. Eugene Hull, III |
| The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1—R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ||||||
| 182 | Process for co-producing commercially valuable products from byproducts of fischer-tropsch process for hydrocarbon fuel formulation in a GTL environment | US14540084 | 2014-11-13 | US09315452B2 | 2016-04-19 | Steve Kresnyak |
| The present invention is directed to the modification of the hydrocarbon production sequence of operations including the Fischer-Tropsch process for the production of hydrocarbon fuels in an efficient manner, along with the production of commercially valuable co-products from by-products of the hydrocarbon production process. | ||||||
| 183 | Pactamycin analogs and methods of making thereof | US12596429 | 2008-04-18 | US08957251B2 | 2015-02-17 | Taifo Mahmud; Takuya Ito; Patricia M. Flatt; Niran Roongsawang; Norifumi Shirasaka |
| This disclosure describes the molecular cloning of a pactamycin biosynthetic gene cluster from Streptomyces pactum ATCC 27456, characterization of individual genes in the gene cluster and the proteins encoded thereby as well as uses thereof. The pactamycin gene cluster is located within an 86.35 kilobases genetic locus and includes 53 open reading frames, 26 of which are considered to be the core cluster directly involved in the biosynthesis of pactamycin. The present disclosure also relates to the use of the pactamycin biosynthetic genes located within the identified gene cluster for drug design and development purposes, including the development of pactamycin analogs that are more efficacious and less toxic. Also provided are drugs and antibiotics so produced, as well as methods of their use. | ||||||
| 184 | Process for solubilizing hydrophobic active ingredients in aqueous medium | US13021190 | 2011-02-04 | US08728504B2 | 2014-05-20 | Bernd Bruchmann; Holger Türk; Daniel Schönfelder; Monika Haberecht; Dietmar Appelhans; Victor Boyko |
| A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide. | ||||||
| 185 | Plant for urea production | US12367240 | 2009-02-06 | US08721975B2 | 2014-05-13 | Ermanno Filippi; Enrico Rizzi; Mirco Tarozzo; Federico Zardi |
| Plant for urea production from ammonia and carbon dioxide having a so-called high-pressure section which comprises a synthesis reactor and a condensation unit (7, 107) positioned inside the reactor, all substantially operating at the same pressure. | ||||||
| 186 | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity | US13300729 | 2011-11-21 | US08507560B2 | 2013-08-13 | Richard L. Beard; John E. Donello; Michael E. Garst; Veena Viswanath |
| The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative. | ||||||
| 187 | Urea granulation process with an acidic scrubbing system and the subsequent integration of ammonium salt into urea granules | US12998733 | 2009-11-06 | US08466315B2 | 2013-06-18 | Paul Niehues; Harald Franzrahe; Matthias Potthoff; Roland Monstrey |
| A urea granulation process and the apparatus suitable for operating that process integrates a method for reducing ammonia emissions from a urea granulation plant which is emitted by a urea production process by scrubbing the off-gas and recovering the scrubber bleed and integrating it into the granulation process so that ammonium salts are completely contained by the process. | ||||||
| 188 | Process for increasing the capacity of an existing urea plant | US12936190 | 2009-03-30 | US08377399B2 | 2013-02-19 | Johannes Henricus Mennen |
| Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure urea synthesis section and a medium-pressure recovery section, is installed, wherein a urea-containing stream is produced from ammonia and carbon dioxide and the urea-containing stream is sent to the existing urea plant where the urea-containing stream is further purified in the low-pressure recovery section. | ||||||
| 189 | Addition compounds suitable as dispersants and dispersion stabilizers | US11123804 | 2005-05-06 | US08362300B2 | 2013-01-29 | Wolfgang Pritschins; Udo Krappe; Karlheinz Haubennestel; Andrea Esser |
| The present invention provides addition compounds, which suitable as dispersants and as dispersion stabilizers, and to the salts of the said compounds. The invention further provides processes for preparing these addition compounds, to their use as dispersants and dispersion stabilizers for organic and inorganic pigments and also fillers in organic and aqueous systems, and to pulverous or fibrous solids coated with such dispersants and intended for incorporation into liquid systems. | ||||||
| 190 | Phenethanolamine derivatives for treatment of respiratory diseases | US13165037 | 2011-06-21 | US08198483B2 | 2012-06-12 | Philip Charles Box; Diane Mary Coe; Brian Edgar Looker; Inderjit Singh Mann; Panayiotis Alexandrou Procopiou |
| (1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol and (5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one are claimed. | ||||||
| 191 | Tetrahydro-naphthalene derivatives | US13052482 | 2011-03-21 | US08173841B2 | 2012-05-08 | Masaomi Tajimi; Toshio Kokubo; Masahiro Shiroo; Yasuhiro Tsukimi; Takeshi Yura; Klaus Urbahns; Noriyuki Yamamoto; Muneto Mogi; Hiroshi Fujishima; Tsutomu Masuda; Nagahiro Yoshida; Toshiya Moriwaki |
| This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. | ||||||
| 192 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | US12599641 | 2008-05-09 | US20110071125A1 | 2011-03-24 | Joachim Rudolph; Jaques Dumas; Li Yingfu; Daniel Auclair; Mario Lobell; Marion Hitchcock; Ingo Hartung; Marcus Koppitz; Dominic Brittain; Florian Puehler; Kirstin Petersen; Judith Guenther; Benjamin Bader |
| This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | ||||||
| 193 | Synthesis of biurets and isocyanates with alkoxysilane functions, formulations containing same and use thereof | US10579808 | 2004-12-16 | US07875693B2 | 2011-01-25 | Jean-Marie Bernard; Johannes Schwarz; Denis Revelant |
| The invention relates to a composition and a method of preparing one such composition and an isocyanatoalkoxysilane; the polyisocyanate composition contains at least two different oligomeric compounds comprising at least three units and at most five units selected from aminoalkylsilane units and diamine units and at least one function selected from isocyanate functions and from those derived therefrom, the aforementioned compounds having at least two aminoalkylsilane units and another compound having at least two diamine units; the invention is suitable for coatings. | ||||||
| 194 | HETEROCYCLIC CETP INHIBITORS | US12797760 | 2010-06-10 | US20100267669A1 | 2010-10-21 | Mark E. Salvati; Heather Finlay; Bang-Chi Chen; Lalgudi S. Harikrishnan; Ji Jiang; James A. Johnson; Muthoni G. Kamau; R. Michael Lawrence; Jianqing Li; John Lloyd; Michael M. Miller; Zulan Pi; Jennifer X. Qiao; Richard A. Rampulla; Jacques Y. Roberge; Tammy C. Wang; Yufeng Wang; Wu Yang |
| Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein. | ||||||
| 195 | Method for Making Carbamates, Ureas and Isocyanates | US12347131 | 2008-12-31 | US20100113819A1 | 2010-05-06 | Hatem Abdallah Belfadhel; Hans-Peter Brack; Ricardo Godoy-Lopez; Dennis James Patrick Maria Willemse |
| The present invention provides methods of forming carbamates, ureas, and isocyanates. In certain embodiments these methods include the step of reacting an amine with an ester-substituted diaryl carbonate to form an activated carbamate which can be further derivitized to form non-activated carbamate or a urea. The urea or carbamate can be subjected to a pyrolysis reaction to form isocyanate. | ||||||
| 196 | Process for preparing allophanate-containing actinically curable polyurethane prepolymers with increased resistance | US11731592 | 2007-03-30 | US07700662B2 | 2010-04-20 | Michael Ludewig; Jan Weikard; Nicolas Stoeckel; Wolfgang Fischer |
| The present invention relates to a process for preparing low-viscosity, allophanate-containing and NCO-free polyurethane prepolymers curable by actinic radiation, and to the products obtainable by this process. The prepolymers have residual monomer contents of less than 0.5% by weight and an NCO content of less than 1% by weight, and are prepared by a process in which A) diisocyanates, B) hydroxy-functional compounds containing groups which react with ethylenically unsaturated compounds on exposure to actinic radiation, and C) polyester, polyether or polycarbonate polyols having a functionality of at least 1.9 and a number-average molecular weight (Mn) of at least 1000 g/mol, D) optionally in the presence of a catalyst, are reacted to form NCO-group-containing prepolymers having radiation-curing groups, which are subsequently reacted E) optionally after addition of monofunctional isocyanates in the presence F) of an allophanatization catalyst to give allophanate-containing prepolymers, the ratio of NCO groups of the compounds from A) to the OH groups of the compounds from B) and C) being 1.45:1.0 to 1.1:1.0 and the ratio of the OH groups from B) to the OH groups from C) being 8.0:1 to 1.5:1. | ||||||
| 197 | CARBAMOYLATION OF AMINES, THIOPHENOLS, MERCAPTANES AND PHENOLS EMPLOYING ORGANIC AZIDES | US12447203 | 2007-10-25 | US20100093981A1 | 2010-04-15 | Andrey Yagodkin; Alex Azhayen |
| The present invention relates to carbamoylation of amines, mercaptanes, thiophenols and phenols employing organic azides. More specifically, the invention relates to a method for generating urea derivatives, thiocarbamate derivatives and carbamate derivatives, and is based on the intermediate formation of isocyanate, starting from an organic azide. The reaction as described is useful in applications for modified nucleoside synthesis, oligonucleotide synthesis, as well as modification, labeling and conjugation of polymers and biomolecules. | ||||||
| 198 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | US11578000 | 2005-10-28 | US20090258858A1 | 2009-10-15 | Jakob Busch-Petersen; Jeffrey Charles Boehm; Huijie Li; John J. Taggart; Hong Xing Yan |
| Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | ||||||
| 199 | Contrast Agents | US12031070 | 2008-02-14 | US20080199404A1 | 2008-08-21 | Hanno Priebe |
| The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto.The invention also relates to methods of diagnosis and imaging employing such diagnostic compositions as contrast agents in particular in X-ray imaging, and to contrast media containing such compounds. | ||||||
| 200 | Stable liquid biuret modified and biuret allophanate modified toluene diisocyanates, prepolymers thereof, and processes for their preparation | US11906642 | 2007-10-03 | US20080033203A1 | 2008-02-07 | William Slack; Rick Adkins; Hersel Kemp |
| This invention relates to stable liquid biuret modified toluene diisocyanates, prepolymers thereof, stable liquid biuret allophanate modified toluene diisocyanates, prepolymers thereof, and to processes for the preparation of these compositions. The stable liquid biuret modified toluene diisocyanates comprise a secondary amine based biuret modified TDI having an NCO group content of about 12 to about 46% by weight. | ||||||
QQ群二维码
意见反馈
意见反馈